Form 4 for INSP Inspire Medical Systems, Inc.
Accepted 2022-12-06 00:00:00 ET · period of report 2022-12-02 · accession 0001104659-22-124890 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-06 | 2022-12-02 | INSP | Ban Randy | Chief Commercial Off | M - OptEx | $0.94 | +10.3K | 10.6K | +3,626% | +$9,713 |
| DM | 2022-12-06 | 2022-12-05 | INSP | Ban Randy | Chief Commercial Off | S - Sale+OE | $235.87 | -10.3K | 5,430 | -66% | -$2.44M |
| DM | 2022-12-06 | 2022-12-02 | INSP | Ban Randy | Chief Commercial Off | M - OptEx | $0.00 | -10.3K | 200 | -98% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-02 | M | A | 10,333 | $0.94 | 10,618 | D | — | — | (F1) Includes 19 additional shares acquired under the Inspire Medical Systems, Inc. 2018 Employee Stock Purchase Plan since the Reporting Person's ownership report filed on January 6, 2022. |
| 2 | Common | Common Stock | 2022-12-05 | S | D | 1,400 | $238.05 | 1,434 | D | — | — | (F2) The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $237.60 to $238.54. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2022-12-05 | S | D | 642 | $236.64 | 2,834 | D | — | — | (F2) The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $236.24 to $237.21. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2022-12-05 | S | D | 1,149 | $239.16 | 285 | D | — | — | (F2) The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $238.66 to $239.60. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2022-12-05 | S | D | 1,954 | $235.29 | 3,476 | D | — | — | (F2) The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.11 to $236.24. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 6 | Common | Common Stock | 2022-12-05 | S | D | 5,188 | $234.68 | 5,430 | D | — | — | (F2) The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.11 to $235.05. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7 | Derivative | Stock Option (Right to Buy) | 2022-12-02 | M | D | 5,000 | $0.00 | 31,090 | D | $0.94 · — to 2027-04-01 | 5,000 Common Stock | (F8) The option is fully vested and exercisable. |
| 8 | Derivative | Stock Option (Right to Buy) | 2022-12-02 | M | D | 5,333 | $0.00 | 200 | D | $0.94 · — to 2027-01-01 | 5,333 Common Stock | (F8) The option is fully vested and exercisable. |